SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 3, 2014 (GLOBE NEWSWIRE) -- Immune Design, a clinical-stage biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced that Carlos Paya, M.D., Ph.D., Chief Executive Officer, will present at two upcoming investor conferences.
16th Annual BIO CEO & Investor Conference
Monday, February 10, 1:15 p.m. Eastern in New York, NY
Leerink Global Healthcare Conference
Thursday, February 13, 1:50 p.m. Eastern in New York, NY
Dr. Paya will discuss Immune Design's clinical immuno-oncology programs, including those under the Specific Antigen approach, ID-LV305 and ID-G305, and the Endogenous Antigen Approach, G-100, as well as the company's discovery platforms, DCVexTM and GLAASTM.
About Immune Design
Immune Design is a clinical-stage biotechnology company employing leading-edge technologies that target in vivo dendritic cells to generate strong cytotoxic T cells (CTLs) for the treatment of cancer and other chronic diseases. The company's clinical programs are the product of its two synergistic discovery platforms: DCVexTM, a novel lentiviral vector platform engineered to deliver antigen-encoding nucleic acids directly to dendritic cells in vivo, and GLAASTM, a TLR4-agonist platform that activates dendritic cells by up-regulating key molecules for efficient antigen presentation and produces Th1 cytokines to enhance the immune response. Immune Design has offices in Seattle, Washington and South San Francisco, California. For more information, visit www.immunedesign.com.
CONTACT: Julie Rathbun Rathbun Communications firstname.lastname@example.org 206.769.9219
Source: Immune Design